Novel Variants and Mosaicism in Pompe Disease Identified by Extended Analyses of Patients with an Incomplete DNA Diagnosis.
Clicks: 348
ID: 101050
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.0
/100
348 views
51 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #1 of 5 articles by views in molecular therapy methods & clinical development
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Pompe disease is a metabolic disorder caused by a deficiency of the glycogen-hydrolyzing lysosomal enzyme acid α-glucosidase (GAA), which leads to progressive muscle wasting. This autosomal-recessive disorder is the result of disease-associated variants located in the gene. In the present study, we performed extended molecular diagnostic analysis to identify novel disease-associated variants in six suspected Pompe patients from four different families for which conventional diagnostic assays were insufficient. Additional assays, such as a generic-splicing assay, minigene analysis, SNP array analysis, and targeted Sanger sequencing, allowed the identification of an exonic deletion, a promoter deletion, and a novel splicing variant located in the 5' UTR. Furthermore, we describe the diagnostic process for an infantile patient with an atypical phenotype, consisting of left ventricular hypertrophy but no signs of muscle weakness or motor problems. This led to the identification of a genetic mosaicism for a very severe GAA variant caused by a segmental uniparental isodisomy (UPD). With this study, we aim to emphasize the need for additional analyses to detect new disease-associated variants and non-Mendelian genotypes in Pompe disease where conventional DNA diagnostic assays are insufficient.
| Reference Key |
in-t-groen2020novelmolecular
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | In 't Groen, Stijn L M;de Faria, Douglas O S;Iuliano, Alessandro;van den Hout, Johanna M P;Douben, Hannie;Dijkhuizen, Trijnie;Cassiman, David;Witters, Peter;Barba Romero, Miguel-Ángel;de Klein, Annelies;Somers-Bolman, Galhana M;Saris, Jasper J;Hoefsloot, Lies H;van der Ploeg, Ans T;Bergsma, Atze J;Pijnappel, W W M Pim; |
| Journal | molecular therapy methods & clinical development |
| Year | 2020 |
| DOI |
10.1016/j.omtm.2019.12.016
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.